Basit öğe kaydını göster

Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

dc.contributor.authorChowdhury, Simon
dc.contributor.authorChung, Byung Ha
dc.contributor.authorGomes, Andrea Juliana Pereira de Santana
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorUemura, Hirotsugu
dc.contributor.authorYe, Dingwei
dc.contributor.authorBrookman-May, Sabine Doris
dc.contributor.authorMundle, Suneel
dc.contributor.authorMcCarthy, Sharon Anne
dc.contributor.authorLefresne, Florence
dc.contributor.authorDibaj, Shiva
dc.contributor.authorBevans, Katherine B.
dc.contributor.authorChi, Kim N.
dc.contributor.authorAgarwal, Neeraj
dc.contributor.authorBjartell, Anders
dc.contributor.authorGiven, Robert
dc.contributor.authorJuarez, Alvaro
dc.contributor.authorMerseburger, Axel Stuart
dc.date.accessioned2021-12-10T12:54:30Z
dc.date.available2021-12-10T12:54:30Z
dc.date.issued2021
dc.identifier.citationAgarwal N., Chowdhury S., Bjartell A., Chung B. H. , Gomes A. J. P. d. S. , Given R., Juarez A., Merseburger A. S. , Ozguroglu M., Uemura H., et al., "Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.identifier.issn0732-183X
dc.identifier.otherav_e0173f4d-0d6f-450b-92ca-c82653d239fa
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/174948
dc.identifier.urihttps://doi.org/10.1200/jco.2021.39.15_suppl.5068
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleHealth-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume39
dc.identifier.issue15
dc.contributor.firstauthorID2769983


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster